Leica Biosystems and Advanced Cell Diagnostics, Inc., (ACD) have announced the co-marketing of ACD's RNAscope LS ISH (in situhybridization) assays with Leica Biosystems' BOND RX research staining platform (for research use only; not for use in diagnostic procedures). This agreement provides researchers with an integrated and fully automated ISH solution. The RNAscope LS reagent kits and ISH probes are available from ACD, while the BOND RX instrument and associated reagents are supplied by Leica Biosystems.
In a press release, ACD representatives say that ACD's RNAscope assays represent a major technological advance for in situ RNA detection. “For the first time, robust single RNA molecule detection is available for formalin-fixed, paraffin-embedded (FFPE) tissue. The RNAscope LS assays are fully automated on the BOND RX platform. This open and flexible system automates staining to provide a fast, high-throughput workflow with exceptional consistency and minimal hands-on time.”
“Automation is essential for pharma, biotech, translational labs, and academic institutions to apply the RNA ISH technology to a wide range of biomarker analysis applications,” says Yuling Luo, PhD, President and CEO of ACD. “We are very pleased to work with Leica Biosystems to expand our automated RNAscope solutions in response to the needs of our rapidly growing customer base.”
David Atkins, PhD, VP Advanced Staining at Leica Biosystems, adds, “Leica is excited to announce the availability of ACD's RNAscope Assays fully automated on the BOND RX. With its openness and flexibility, the BOND RX is providing researchers with enhanced tools to help speed up important discoveries and improve cancer diagnostics.” Learn more about the RNAscope Assays.
Read more
